AKTX

Akari is a pre-revenue, preclinical oncology company whose entire value rests on AKTX-101, a Trop-2 ADC that management concedes has not even entered clinical development: the 10-K states 'we have not initiated clinical development of any of the product candidates in our active pipeline and expect that it will be many years, if ever, before any of our candidates is ready for commercialization.' There is no product, no revenue in any year FY2021–FY2025, and a five-year string of losses (-$17.3M in FY2025) that has built an accumulated deficit of -$265M. This is a binary science bet, not a business, and the numbers say the clock is running out.

The balance sheet is the disqualifier. The filing discloses cash of ~$5.2 million against operating cash burn of -$10.6M — well under a year of runway — and management explicitly warns that inadequate funding 'raises substantial doubt about our ability to continue as a going concern.' Current liabilities ($12.4M) exceed current assets ($5.46M), so working capital is negative. Survival depends entirely on raising capital 'on terms that are acceptable to us, or at all,' which the company admits is not assured.